title: Reasons for prescribing second generation antihistamines to treat allergic rhinitis in real-life conditions and patient response.
abstract: BACKGROUND
  Second generation H1 antihistamines (H1A) are currently recommended as first choice medications for allergic rhinitis and rhinoconjunctivitis. However, little is known about what influences the choice of prescription of one second generation (H1A) as opposed to another in real-life conditions.
  
  
  OBJECTIVE
  The aim of the study was to identify the main criteria determining the choice of a second generation H1A by allergy specialists in mainland France.
  
  
  METHODS
  Consecutive patients suffering from allergic rhinitis or rhinoconjunctivitis were included and followed prospectively for 30 days from the prescription of a second generation H1A in monotherapy. Patients were asked to fill in auto-questionnaires at baseline, daily during the first 10 days of the new treatment, and at the end of follow-up. Data on efficacy, tolerance, safety, rate and type of response to treatment, as well as patient satisfaction were recorded and analyzed.
  
  
  RESULTS
  1,080 patients were included between March 2011 and October 2012, mostly suffering from moderate to severe rhinitis (82.0%). The most frequently cited reason for choosing a specific H1A was the expected efficacy (85.3%). The mean time to nasal and ocular recovery was 6 days and 78.2% of patients responded to treatment within this interval. The presence of conjunctivitis was significantly associated with a more rapid response. At the end of follow-up, the satisfaction rate was higher for patients who were switched from a previous treatment (87.5%), compared to those receiving their first treatment (78.8%).
  
  
  CONCLUSIONS
  The main reason for choosing a specific second generation H1A was its expected efficacy. Concomitant conjunctivitis is associated with a more rapid response to treatment. Symptom recovery necessitates a mean of 6 days.
authors.affiliation: Département de Pneumologie et Addictologie, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, France; and Sorbonne Universités, UPMC Paris 06, UMR-S 1136, IPLESP, Equipe EPAR, 75013 Paris, France.
authors.forename: Pascal
authors.initials: P
authors.lastname: Demoly
authors.affiliation: Département de Pneumologie et Addictologie, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, France; and Sorbonne Universités, UPMC Paris 06, UMR-S 1136, IPLESP, Equipe EPAR, 75013 Paris, France.
authors.forename: Anca Mirela
authors.initials: AM
authors.lastname: Chiriac
authors.affiliation: EURAXI PHARMA, 10 rue Gutenberg, BP 80325, 37303 Joué-les-Tours, France.
authors.forename: Benoît
authors.initials: B
authors.lastname: Berge
authors.affiliation: Medical Affairs Department, Pierre Fabre Médicament, 81106 Castres Cedex, France.
authors.forename: Michel
authors.initials: M
authors.lastname: Rostin
keywords: Allergic rhinitis; Quality of life; Second generation antihistamine